循環(huán)中Hsa-miR-9、Hsa-miR-21、Hsa-miR-501的表達(dá)水平與非小細(xì)胞肺癌的相關(guān)性研究
發(fā)布時(shí)間：2018-09-04 07:57
【摘要】：[目的]1.檢測(cè)非小細(xì)胞肺癌患者血清、血漿中miR-9、miR-21和miR-501的表達(dá)水平,探討miR-9、miR-21和miR-501是否可能作為敏感性高、特異性強(qiáng)的非小細(xì)胞肺癌患者外周血miRNA的生物標(biāo)志物。2.分析對(duì)比非小細(xì)胞肺癌患者、健康人血清與血漿中上述miRNA的表達(dá)差異,探索血清與血漿中的miRNA表達(dá)水平的差異。3.分析非小細(xì)胞肺癌患者血清、血漿中上述miRNA的表達(dá)水平與臨床病理參數(shù)的關(guān)系并與目前臨床上使用的血清腫瘤標(biāo)志物對(duì)比,探索上述miRNA是否可用于監(jiān)測(cè)非小細(xì)胞肺癌復(fù)發(fā)轉(zhuǎn)移、評(píng)價(jià)治療療效及評(píng)估預(yù)后,并探討上述miRNA能否成為宣威肺癌的特異性的生物標(biāo)志物。[方法]1.收集符合入組標(biāo)準(zhǔn)的病人的病例資料,于患者入院后第二天清晨空腹靜脈采血(抗凝血10ml、非抗凝血10ml),分別分離血清、血漿,儲(chǔ)存于潔凈離心管中置于-80℃儲(chǔ)存?zhèn)溆?設(shè)置健康人為對(duì)照組。2.分別提取健康人組、非小細(xì)胞肺癌患者組血清、血漿中的miRNA,再采用qRT-PCR技術(shù)對(duì)miR-9、miR-21和miR-501進(jìn)行擴(kuò)增,檢測(cè)上述miRNA的表達(dá)量,比較各組miR-9、miR-21和miR-501表達(dá)水平的高低。miR-9、miR-21和miR-501的相對(duì)表達(dá)量的公式為:2-△△CT。3.將所測(cè)患者miR-9、miR-21和miR-501按宣威與非宣威地區(qū)、男性與女性分組進(jìn)行統(tǒng)計(jì)分析。4.分析血清、血漿中miR-9、miR-21和miR-501的表達(dá)水平與肺癌各臨床病理參數(shù)及血清腫瘤標(biāo)志物的水平的相關(guān)性。5.分別計(jì)算miR-9、miR-21和miR-501和血清腫瘤標(biāo)志物CEA、CA125、CA153、CA199、CA242、CA724、FER、CYFRA21-1、NSE、SCC 的靈敏度和特異度,計(jì)算ROC曲線下面積。[結(jié)果]1.血清和血漿miR-9、miR-21在健康人、非小細(xì)胞肺癌患者中表達(dá)水平高,差異有統(tǒng)計(jì)學(xué)意義(P0.05), miR-501在健康人、非小細(xì)胞肺癌患者中表達(dá)差異沒(méi)有統(tǒng)計(jì)學(xué)意義(P0.05)。2.血清miR-9表達(dá)水平健康組為:1.15±0.76,非小細(xì)胞肺癌組為:3.39±3.75;與健康人組相較,非小細(xì)胞肺癌組表達(dá)水平高于健康人組,兩組差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。血清miR-21表達(dá)水平健康組為:0.87±0.29,非小細(xì)胞肺癌組為:2.3±3.02;與健康人組相較,非小細(xì)胞肺癌組表達(dá)水平高于健康人組,兩組差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。血清miR-501表達(dá)水平健康組為:1.84±2.04,非小細(xì)胞肺癌組:2.30±3.02;與健康人組相較,非小細(xì)胞肺癌組表達(dá)水平高于健康人組,兩組差異沒(méi)有統(tǒng)計(jì)學(xué)意義(P0.05)。血漿miR-9表達(dá)水平健康組為:1.12±0.70,非小細(xì)胞肺癌組:3.41±3.73;與健康人組相較,非小細(xì)胞肺癌組表達(dá)水平高于健康人組,兩組差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。血漿miR-21表達(dá)水平健康組為:0.84±0.32,非小細(xì)胞肺癌組:2.37±3.04;與健康人組相較,非小細(xì)胞肺癌組表達(dá)水平高于健康人組,兩組差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。血漿miR-501表達(dá)水平健康組為:1.84±2.06,肺癌組:3.27±3.60;與健康人組相較,非小細(xì)胞肺癌組表達(dá)水平高于健康人組,兩組差異沒(méi)有統(tǒng)計(jì)學(xué)意義(P0.05)。3.對(duì)比非小細(xì)胞肺癌的血清和血漿中表達(dá)miR-9、miR-21、miR-501的水平,不論在非小細(xì)胞肺癌組還是健康組表達(dá)差異,P值均0.05,相關(guān)系數(shù)接近1,P0.001。4.分析外周血循環(huán)中miR-9和miR-21的表達(dá)水平與各臨床病理參數(shù)有無(wú)相關(guān)性,提示miR-9和miR-21的表達(dá)高低與是否宣威籍不相關(guān),miR-9和miR-21的表達(dá)與性別、年齡、TNM分期、轉(zhuǎn)移均不相關(guān)(P0.05)。miR-21與病理類型不相關(guān)(P0.05), miR-9與病理類型存在相關(guān)性(P0.05)。5.外周血循環(huán)中miR-9水平升高與NSE,Cyfra21-1升高有關(guān),(P0.05),外周血循環(huán)中miR-21水平升高與FER、Cyfra21-1、NSE、CA153升高有關(guān),(P0.05)。6.檢測(cè)非小細(xì)胞肺癌患者外周血循環(huán)中miR-9、miR-21的特異性和敏感性均沒(méi)有完全優(yōu)于腫瘤標(biāo)志物 CEA、CA125、CA153、CA199、CA242、CA724、FER、CYFRA-12、NSE、SCC,其中miR-9的ROC曲線下面積達(dá)到0.75,具有診斷準(zhǔn)確性中等。7.四種聯(lián)合腫瘤標(biāo)志物(miR-9, CEA, CA724, CYFRA21-1)特異性95.0%,敏感性82.0%, ROC曲線下面積為0.950,診斷準(zhǔn)確性較高。[結(jié)論]1.miR-9和miR-21在非小細(xì)胞肺癌患者外周血循環(huán)中高表達(dá),提示檢測(cè)外周血循環(huán)中miR-9和miR-21的表達(dá)水平可用于非小細(xì)胞肺癌腫瘤的診斷,外周血循環(huán)中miR-9和miR-21具有成為非小細(xì)胞肺癌生物標(biāo)志物的潛能。2.外周血循環(huán)中miRNAs表達(dá)在血清及血漿中對(duì)比沒(méi)有差異。3.聯(lián)合監(jiān)測(cè)miR-9和CEA,CA724,CYFRA21-1的表達(dá)水平可以提高非小細(xì)胞肺癌的診斷準(zhǔn)確率、降低假陽(yáng)性率,更具有特異性和靈敏性。
[Abstract]:[Objective] 1. To detect the expression of microRNA-9, microRNA-21 and microRNA-501 in serum and plasma of patients with non-small cell lung cancer (NSCLC), and to explore the possibility of microRNA-9, microRNA-21 and microRNA-501 as biomarkers in peripheral blood of NSCLC patients with high sensitivity and specificity. To explore the expression of microRNAs in serum and plasma. 3. To analyze the relationship between the expression of microRNAs in serum and plasma and clinicopathological parameters in patients with non-small cell lung cancer, and to compare the expression of microRNAs with serum tumor markers currently used in clinic, to explore whether the microRNAs can be used to monitor the recurrence of non-small cell lung cancer. [Methods] 1. To collect the case data of patients who met the admission criteria and collect the fasting blood (anticoagulant 10ml, non-anticoagulant 10ml) in the morning after admission. Serum and plasma were separated and stored in Jie. MicroRNAs were extracted from serum and plasma of healthy people, non-small cell lung cancer patients, and amplified by qRT-PCR to detect the expression of microRNAs. The expression levels of microRNAs were compared among the three groups. The relative expression of microRNAs-21 and microRNAs-501 was formulated as follows: 2-delta CT.3. The expression levels of microRNAs-9, microRNAs-21 and microRNAs-501 in serum, plasma and clinical pathological parameters of lung cancer and serum tumor markers were analyzed. The sensitivity and specificity of serum tumor markers CEA, CA125, CA153, CA199, CA242, CA724, FER, CYFRA21-1, NSE and SCC were calculated respectively, and the area under ROC curve was calculated. [Results] 1. The expression levels of serum and plasma microRNAs-9, microRNA21 in healthy people and patients with non-small cell lung cancer were high, and the difference was statistically significant (P 0.05). There was no significant difference in the expression of - 501 between healthy and non-small cell lung cancer patients (P 0.05). 2. The expression level of serum microRNA-9 in healthy group was 1.15 [0.76] and non-small cell lung cancer group was 3.39 [3.75]. Compared with healthy group, the expression level of non-small cell lung cancer group was higher than that in healthy group, the difference was statistically significant (P 0.05). The expression level of serum microRNAs-501 in healthy group was 1.84 [2.04] and that in non-small cell lung cancer group was 2.30 [3.02] and that in healthy group was higher than that in healthy group (P 0.05). The expression level of serum microRNAs-501 in healthy group was 1.84 [2.04] and that in non-small cell lung cancer group was 2.30 [3.02] respectively. There was no significant difference between the two groups (P 0.05). The expression level of plasma microRNAs-9 in healthy group was 1.12 [0.70] and that in non-small cell lung cancer group was 3.41 [3.73]. Compared with healthy group, the expression level of plasma microRNAs-21 in non-small cell lung cancer group was higher than that in healthy group, the difference was statistically significant (P 0.05). The expression level of plasma microarray-501 in healthy group was 1.84 [2.06] and that in lung cancer group was 3.27 [3.60] and that in non-small cell lung cancer group was higher than that in healthy group (P 0.05). There was no significant difference between the two groups (P The expression of microRNA-9 and microRNA-21 was not correlated with sex, age, TNM stage and metastasis (P 0.05). MicroRNA-21 was not correlated with pathological type (P 0.05). MicroRNA-9 was correlated with pathological type (P 0.05). The level of microRNA-9 in peripheral blood circulation increased (P 0.05). The increased levels of microRNAs in peripheral blood circulation were associated with the increased levels of FER, Cyfra21-1, NSE and CA153, (P 0.05). 6. The specificity and sensitivity of detecting microRNAs-9 and microRNAs-21 in peripheral blood circulation of patients with non-small cell lung cancer were not completely superior to those of tumor markers CEA, CA125, CA153, CA199, CA242, CA724, FER, CYFRA-12, NSE, SC, CA242, CA724, FER, CYFRA-12, NSE, and SCE. Among them, the area under the ROC curve of microRNAs-9 was 0.75, and the diagnostic accuracy was moderate. 7. The specificity, sensitivity and area under the ROC curve of the four combined tumor markers (microRNAs-9, CEA, CA724, CYFRA21-1) were 95.0%, 82.0% and 0.950 respectively. The diagnostic accuracy of microRNAs-9 and microRNAs-21 was high in peripheral blood circulation of non-small cell lung cancer patients. Detecting the expression of microRNA-9 and microRNA-21 in peripheral blood circulation can be used for the diagnosis of non-small cell lung cancer. MicroRNA-9 and microRNA-21 in peripheral blood circulation have the potential to become biomarkers of non-small cell lung cancer. The expression level can improve the diagnostic accuracy of non-small cell lung cancer, reduce the false positive rate, and is more specific and sensitive.
【學(xué)位授予單位】：昆明醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R734.2
本文編號(hào)：2221471
[Abstract]:[Objective] 1. To detect the expression of microRNA-9, microRNA-21 and microRNA-501 in serum and plasma of patients with non-small cell lung cancer (NSCLC), and to explore the possibility of microRNA-9, microRNA-21 and microRNA-501 as biomarkers in peripheral blood of NSCLC patients with high sensitivity and specificity. To explore the expression of microRNAs in serum and plasma. 3. To analyze the relationship between the expression of microRNAs in serum and plasma and clinicopathological parameters in patients with non-small cell lung cancer, and to compare the expression of microRNAs with serum tumor markers currently used in clinic, to explore whether the microRNAs can be used to monitor the recurrence of non-small cell lung cancer. [Methods] 1. To collect the case data of patients who met the admission criteria and collect the fasting blood (anticoagulant 10ml, non-anticoagulant 10ml) in the morning after admission. Serum and plasma were separated and stored in Jie. MicroRNAs were extracted from serum and plasma of healthy people, non-small cell lung cancer patients, and amplified by qRT-PCR to detect the expression of microRNAs. The expression levels of microRNAs were compared among the three groups. The relative expression of microRNAs-21 and microRNAs-501 was formulated as follows: 2-delta CT.3. The expression levels of microRNAs-9, microRNAs-21 and microRNAs-501 in serum, plasma and clinical pathological parameters of lung cancer and serum tumor markers were analyzed. The sensitivity and specificity of serum tumor markers CEA, CA125, CA153, CA199, CA242, CA724, FER, CYFRA21-1, NSE and SCC were calculated respectively, and the area under ROC curve was calculated. [Results] 1. The expression levels of serum and plasma microRNAs-9, microRNA21 in healthy people and patients with non-small cell lung cancer were high, and the difference was statistically significant (P 0.05). There was no significant difference in the expression of - 501 between healthy and non-small cell lung cancer patients (P 0.05). 2. The expression level of serum microRNA-9 in healthy group was 1.15 [0.76] and non-small cell lung cancer group was 3.39 [3.75]. Compared with healthy group, the expression level of non-small cell lung cancer group was higher than that in healthy group, the difference was statistically significant (P 0.05). The expression level of serum microRNAs-501 in healthy group was 1.84 [2.04] and that in non-small cell lung cancer group was 2.30 [3.02] and that in healthy group was higher than that in healthy group (P 0.05). The expression level of serum microRNAs-501 in healthy group was 1.84 [2.04] and that in non-small cell lung cancer group was 2.30 [3.02] respectively. There was no significant difference between the two groups (P 0.05). The expression level of plasma microRNAs-9 in healthy group was 1.12 [0.70] and that in non-small cell lung cancer group was 3.41 [3.73]. Compared with healthy group, the expression level of plasma microRNAs-21 in non-small cell lung cancer group was higher than that in healthy group, the difference was statistically significant (P 0.05). The expression level of plasma microarray-501 in healthy group was 1.84 [2.06] and that in lung cancer group was 3.27 [3.60] and that in non-small cell lung cancer group was higher than that in healthy group (P 0.05). There was no significant difference between the two groups (P The expression of microRNA-9 and microRNA-21 was not correlated with sex, age, TNM stage and metastasis (P 0.05). MicroRNA-21 was not correlated with pathological type (P 0.05). MicroRNA-9 was correlated with pathological type (P 0.05). The level of microRNA-9 in peripheral blood circulation increased (P 0.05). The increased levels of microRNAs in peripheral blood circulation were associated with the increased levels of FER, Cyfra21-1, NSE and CA153, (P 0.05). 6. The specificity and sensitivity of detecting microRNAs-9 and microRNAs-21 in peripheral blood circulation of patients with non-small cell lung cancer were not completely superior to those of tumor markers CEA, CA125, CA153, CA199, CA242, CA724, FER, CYFRA-12, NSE, SC, CA242, CA724, FER, CYFRA-12, NSE, and SCE. Among them, the area under the ROC curve of microRNAs-9 was 0.75, and the diagnostic accuracy was moderate. 7. The specificity, sensitivity and area under the ROC curve of the four combined tumor markers (microRNAs-9, CEA, CA724, CYFRA21-1) were 95.0%, 82.0% and 0.950 respectively. The diagnostic accuracy of microRNAs-9 and microRNAs-21 was high in peripheral blood circulation of non-small cell lung cancer patients. Detecting the expression of microRNA-9 and microRNA-21 in peripheral blood circulation can be used for the diagnosis of non-small cell lung cancer. MicroRNA-9 and microRNA-21 in peripheral blood circulation have the potential to become biomarkers of non-small cell lung cancer. The expression level can improve the diagnostic accuracy of non-small cell lung cancer, reduce the false positive rate, and is more specific and sensitive.
【學(xué)位授予單位】：昆明醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R734.2
【參考文獻(xiàn)】
相關(guān)期刊論文 前7條
1 楊加鵬;黃云超;資文華;白云寶;李光劍;葉聯(lián)華;周永春;趙光強(qiáng);雷玉潔;陳小波;陳穎;張艷軍;;基于宣威地區(qū)“開放式火塘”的實(shí)驗(yàn)裝置研究[J];生物醫(yī)學(xué)工程學(xué)雜志;2016年01期
2 楊加鵬;黃云超;李光劍;葉聯(lián)華;趙光強(qiáng);雷玉潔;陳小波;曹宇;田林瑋;;宣威地區(qū)所產(chǎn)煙煤燃燒產(chǎn)出可吸入細(xì)顆粒物與肺癌發(fā)病的關(guān)系研究[J];中國(guó)肺癌雜志;2015年07期
3 任開明;石文君;;血清CEA水平與肺腺癌TNM分期、治療方法及生存率的相關(guān)性分析[J];山東醫(yī)藥;2011年42期
4 陳小波;雷玉潔;趙光強(qiáng);楊凱云;黃云超;;宣威地區(qū)女性肺癌與8-羥基脫氧鳥苷的關(guān)系[J];腫瘤防治研究;2011年10期
5 楊凱云;黃云超;趙光強(qiáng);雷玉潔;王昆;;宣威女性肺癌患者肺組織中PAHS-DNA加合物的表達(dá)[J];中國(guó)肺癌雜志;2010年05期
6 錢孟佼;黃云超;;云南宣威肺癌與納米級(jí)石英氧化損傷核因子NF-κB高表達(dá)的關(guān)系[J];中國(guó)肺癌雜志;2009年11期
7 李光劍;黃云超;田林瑋;劉擁軍;郭律;肖義澤;侯文俊;楊X;陳穎;趙光強(qiáng);雷玉潔;;云南省宣威地區(qū)非吸煙女性肺癌與C1煙煤中二氧化硅的關(guān)系[J];中華勞動(dòng)衛(wèi)生職業(yè)病雜志;2013年01期
，本文編號(hào)：2221471
本文鏈接：http://www.sikaile.net/yixuelunwen/zlx/2221471.html
最近更新
教材專著
